And in China and European countries sildenafil bioequivalence study.

BioNano Genomics announces $10M financing for advancement of Irys Program for genome analysis BioNano Genomics announced today a $10 million funding to aid the ongoing advancement and commercialization of the IrysTM Program for human genome evaluation sildenafil bioequivalence study click here . BioNano Genomics has produced significant improvement in commercializing the Irys Program 1st in the U.S. And in China and European countries, to expand the global usage of the billed power of its long-read capabilities, stated Tracy Warren, general partner of Battelle Ventures. We continue our support of BioNano in order that researchers and clinicians could have better tools to research the clinical need for genome variation.